September 1999
Volume 40, Issue 10
Free
Physiology and Pharmacology  |   September 1999
Characterization of α2 Adrenergic Receptor Subtypes in Human Ocular Tissue Homogenates
Author Affiliations
  • David B. Bylund
    From the Departments of Pharmacology and
  • David M. Chacko
    Ophthalmology, University of Nebraska Medical Center, Omaha.
Investigative Ophthalmology & Visual Science September 1999, Vol.40, 2299-2306. doi:
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      David B. Bylund, David M. Chacko; Characterization of α2 Adrenergic Receptor Subtypes in Human Ocular Tissue Homogenates. Invest. Ophthalmol. Vis. Sci. 1999;40(10):2299-2306.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

purpose. To determine the predominant α2 adrenergic receptor subtypes present in the human eye.

methods. Saturation- and competition-receptor–binding experiments were performed with the radioligand [3H]RX821002 in human ciliary body, retinal pigmented epithelium–choriocapillaris, iris, and neurosensory retina. The affinities of various adrenergic antagonists in these ocular tissues were compared with their affinities for the cloned α2A, α2B, and α2C adrenergic receptor subtypes.

results. The density of α2 adrenergic receptors was highest in the iris (440 femtomoles/mg protein), lowest in the neurosensory retina (14 femtomoles/mg protein), and intermediate in the other two tissues (approximately 90 fmol/mg protein). The drug affinities in all four human ocular tissues were highly correlated (correlation coefficients between 0.94 and 0.97) with the affinities for the humanα 2A adrenergic receptor subtype and poorly correlated (correlation coefficients between 0.15 and 0.66) with theα 2B and α2C subtypes.

conclusions. In agreement with previous studies in several animal species, theα 2 adrenergic receptors in the human ciliary body, retinal pigmented epithelium–choriocapillaris, iris, and neurosensory retina are predominately of the α2A subtype.

Glaucoma is characterized by a progressive loss of visual sensitivity resulting from optic nerve damage. Because high intraocular pressure is the most important risk factor for glaucoma, the treatment of glaucoma has emphasized the reduction of intraocular pressure. 1 Alpha-2 adrenergic agonists such as brimonidine and apraclonidine are effective ocular hypotensive agents, 2 3 4 although their mechanism of action is not clear. 5 6 7 The development of subtype-selectiveα 2 adrenergic agents for topical application is desirable to reduce both systemic and ocular side effects. An understanding of the distribution of α2 receptor subtypes in the eye would be useful in designing new drugs with greater effectiveness and fewer adverse effects. 
Based on both pharmacologic and molecular evidence, there are three major types of adrenergic receptors, α12, and β, each of which is further divided into three or four subtypes. 8 The evidence for α2 adrenergic receptor subtypes has come from binding and functional studies in various tissues and cell lines and more recently in cells transfected with the cDNA for the receptors. 9 On the basis of these studies, three α2 adrenergic receptor subtypes have been defined. The α2A adrenergic receptor subtype, for which prazosin has a relatively low affinity and oxymetazoline a relatively high affinity, is found in the human platelet and the HT29 cell. 8 The second subtype, the α2B, was identified in neonatal rat lung and in the NG108 cell. 10 This subtype has a relatively high affinity for prazosin and a low affinity for oxymetazoline. A third subtype, the α2C, has been identified in an opossum kidney cell line. 11 Although this subtype also has a relatively high affinity for prazosin and a low affinity for oxymetazoline, it is pharmacologically distinct from theα 2B subtype. 12 All three subtypes have been cloned from the human. 13 14 15 Using the homogenate radioligand-binding technique, α2 adrenergic receptors have been identified in ocular tissues of several species, including the ciliary body, retinal pigmented epithelium (RPE)–choriocapillaris, iris, and neurosensory retina of both the cow 16 17 and the pig 18 and the ciliary body of the rabbit. 19 The results of these binding studies indicate that theα 2A subtype is the predominant, if not the only,α 2 adrenergic subtype in these ocular tissues, with the exception of the porcine neurosensory retina, which may contain a very low density (4 femtomoles/mg protein) of the α2C subtype. Although similar binding studies have not yet been conducted with human ocular tissues, it appears likely that the predominant human ocularα 2 adrenergic subtype may also be the α2A
In contrast to these binding data, immunofluorescence labeling of the human ciliary body indicates the presence of α2B andα 2C subtypes, but not the α2A subtype. 20 Similarly, studies using polymerase chain reaction (PCR) suggest the presence of the α2B andα 2C subtypes, but not the α2A subtype, in a transformed cell line of human nonpigmented epithelium 20 and only the α2B subtype in the human ciliary body. 21 To determine whether this apparent discrepancy is the result of species differences or of differences in techniques, we investigated the α2 subtypes in human ocular tissues by the radioligand-binding technique. On the basis of receptor-binding experiments using theα 2 antagonist radioligand[ 3H]RX821002, we conclude that theα 2 adrenergic receptors in the human ciliary body, RPE–choriocapillaris, iris, and neurosensory retina are predominately of the α2A subtype. 
Methods
Drugs and Chemicals
[3H]RX821002 (specific activity 52–59 Ci/millimole) was obtained from Amersham International (London, UK); rauwolscine, WB 4101, and spiroxatrine from Research Biochemicals, (Natick, MA); and oxymetazoline from Sigma (St. Louis, MO). Prazosin and ARC-239 were generous gifts from Pfizer (Groton, CT) and Boehringer–Ingelheim (Ridgefield, CT), respectively. Drugs were prepared as 5- or 10-mM stock solutions and diluted in 5 mM HCl. The stock solution for prazosin was in methanol, for spiroxatrine in 80% dimethyl sulfoxide-20% 1 M HCl, and for all other drugs in 5 mM HCl. 
Tissue
Human eyes were obtained frozen from the Missouri Lions Eye Bank and bisected at approximately 7 to 8 mm posterior to the limbus while bathed in 50 mM Tris buffer at 4°C. Under a dissecting microscope, the anterior hyaloid face and lens material were carefully dissected from the iris and ciliary body. The remnants of neurosensory retina, RPE, and choriocapillaris were removed from their attachments at the ora serrata in the anterior portion of the bisected globe. The iris was then removed by disinserting the iris root from the base of the ciliary body, thus releasing the base of the ciliary body then released from its attachment to the scleral spur anteriorly. 
The various tissues were suspended in 25 ml ice-cold 50 mM Tris-HCl (pH 8 at 25°C) and homogenized (model TR-10 Tissumiser; Tekmar, Cincinnati, OH). The homogenate was filtered through a 53-μm nylon mesh, centrifuged at 1400 rpm for 10 minutes. The supernatant was transferred to another tube, recentrifuged at 20,000 rpm for 10 minutes and the pellet frozen at −80°C. 
Radioligand-Binding Assays
Saturation- and competition-binding experiments were performed as described previously, using 25 mM sodium phosphate buffer at pH 7.4. 16 17 22 Briefly, saturation experiments were performed using two sets of duplicate tubes that contained 970 μl of membrane suspension and 20 μl [3H]RX821002. The protein concentration was adjusted to ensure that the specifically bound radioligand was less than 10% of the total added radioligand. One set of tubes contained 10 μl (−)-norepinephrine (final concentration, 100 μM) to determine nonspecific binding. Specific binding was calculated as the difference between total and nonspecific binding. After a 40-minute incubation at room temperature, the suspensions were filtered through glass fiber filter strips (GF/B; Whatman, Clifton, NJ), which had been soaked overnight in 0.1% polyethylenimine, using a 48-sample manifold (Brandel Cell Harvester; Biomedical Research and Development, Gaithersburg, MD). The tubes and filters were washed twice with 5 ml ice-cold 50 mM Tris-HCl (pH 8.0), and the radioactivity on the filter was determined by liquid scintillation spectroscopy. The K d and maximum binding (B max) values were calculated from nonlinear regression of bound versus free ligand concentrations using a statistical software program (Prism; GraphPad, San Diego, CA). K d values are geometric means and B max values are arithmetic means. Protein concentrations were determined by the method of Bradford 23 with bovine serum albumin as the standard. 
For inhibition experiments, 20 μl of a fixed concentration of radioligand [3H]RX821002 (final concentration, 0.24 ± 0.04 nM, which is near the K d concentration) and various concentrations of unlabeled drug (10 μl) were added to duplicate tubes containing 970 μl of the membrane suspension. Assays were then performed as described for saturation experiments. Competition binding data were analyzed (Prism; GraphPad) to determine the 50% inhibitory concentration (IC50) assuming a one-site model. The pseudo Hill slope was determined by fitting the data to the four-parameter logistic equation. In some cases, the fit of the data to a one-site model was compared with the fit to a two-site model. IC50 values were converted to K i values by the method of Cheng and Prusoff 24 and are presented as geometric means. 
Results
The selective α2 adrenergic antagonist[ 3H]RX821002 demonstrated saturable and high-affinity binding to membrane preparations from human ocular tissues (Fig. 1 A). The density of receptor-binding sites (B max) was highest in the iris, intermediate in the ciliary body and RPE–choriocapillaris, and lowest in the neurosensory retina (Table 1) . The density was 30 times higher in the iris than in the neurosensory retina, and 5 times higher than in the ciliary body and RPE–choriocapillaris. The data were linear when plotted by the method of Rosenthal, 25 consistent with [3H]RX821002 binding to a single class of sites (Fig. 1B) . The affinity (K d) of [3H]RX821002 was essentially identical in the ciliary body, iris, and RPE–choriocapillaris but slightly lower (higher K d) in the neurosensory retina (Table 1) . The K d values for these ocular tissues are similar to those obtained under identical binding conditions for the cloned α2A subtype (0.25 nM), but lower than those for the α2B and α2C subtypes (0.89 and 0.58 nM, respectively), 22 indicating that the α2A may be the major subtype in these tissues. 
Inhibition radioligand-binding experiments were used to investigate further which α2 adrenergic receptor subtypes are present in human ocular tissues. In the ciliary body, various adrenergic agents inhibited [3H]RX821002 binding with the expected rank order for an α2A receptor (Fig. 2) . With the exception of the agonist norepinephrine, none of the slope factors (pseudo Hill coefficients) was significantly less than 1.0, indicating the presence of a single major receptor subtype. Oxymetazoline was approximately 300 times more potent than prazosin in inhibiting [3H]RX821002 binding (Table 2) , similar to the 100-fold difference found for the clonedα 2A subtype and much different from the prazosin and oxymetazoline ratios of 0.04 and 0.35 found for the clonedα 2B and α2C subtypes, respectively. 26 The affinities of the antagonists used for the α2B and α2C subtypes relative to theα 2A subtype are shown in Table 3 . The large range of relative affinities (230–0.02) indicates that this set of agents can easily differentiate the α2A subtype from the α2B and α2C subtypes. The K i values determined for the iris, RPE–choriocapillaris, and neurosensory retina were very similar to those of the ciliary body (Table 2) , indicating that theα 2A subtype is also the predominant α2 adrenergic receptor subtype in these tissues. 
To compare the affinities in the four tissues more systematically, the logarithms of the K i values (pK i values) of the six antagonists listed in Table 2 , as well as the K d values of[ 3H]RX821002 for the ciliary body, were plotted against those for the other three tissues (Fig. 3) . In all three cases, the correlation coefficients were close to 1.0, indicating that the same subtype is present in all four tissues. Similarly, the pK i values for the ciliary body were correlated with the pK i values obtained previously for the three cloned human subtypes (Fig. 4) . The values for the ciliary body correlated highly with those for the human α2A subtype (r = 0.97) but poorly with the α2B (r = 0.22) and the α2C (r = 0.50) subtypes. Similar results were obtained for the other three human ocular tissues (Table 4)
Although these data clearly indicate that the α2A subtype is the predominant α2 adrenergic receptor subtype in human ocular tissues, the possibility of a low density of an additionalα 2 subtype cannot be excluded. In the porcine neurosensory retina, for example, 85% of the receptors areα 2A, but 15% are α2C. 18 Furthermore, the α2C subtype is the main α2 receptor in a human retinoblastoma cell line (Y79). 27 These observations prompted a more careful evaluation of the data. The K d value for [3H]RX821002 was somewhat higher in the neurosensory retina than in the other tissues (Table 1) . Similarly, in the neurosensory retina the slope factors for many of the antagonists were less than 1.0. Spiroxatrine has a 40-fold higher affinity for the human α2C subtype, compared with the α2A, and thus is a good antagonist for detecting a minor amount of α2C in the presence of theα 2A subtype. If a measurable amount of α2C were present in the neurosensory retina, then the spiroxatrine inhibition data should fit a two-site model better than a one-site model. In four of six inhibition experiments in the neurosensory retina, the data fit a two-site model significantly better than a one-site model (P < 0.05). For the four experiments that modeled better as two sites, the higher affinity site had a median effective concentration (EC50) of 1.4 nM and accounted for 56% of the receptors, whereas the lower affinity site had an EC50 of 72 nM. When the data for all six experiments were combined and fit as a single curve, similar results were obtained (Fig. 5) . Thus, it appears likely that the human neurosensory retina contains a significant amount of both the α2A and α2C subtypes. 
Discussion
Alpha-2 adrenergic agents, such as brimonidine and apraclonidine, effectively lower intraocular pressure, although the mechanisms involved are not yet well understood. Three presumed sites of action for these agonists are the ciliary nonpigmented epithelium (reduction of aqueous humor production), ciliary muscle (increase in uveoscleral outflow facility), and the trabecular meshwork (increase in trabecular outflow). In addition, in some species a central site of action forα 2 agonists is also probable. Brimonidine and apraclonidine are equally efficacious in decreasing aqueous humor production, 28 presumably by acting on the nonpigmented epithelium of the ciliary body. However, brimonidine 7 and oxymetazoline 29 also appear to increase uveoscleral outflow, whereas apraclonidine increases outflow through the trabecular meshwork. 6 One potential explanation for these differences is that the agonists have differential potencies at the threeα 2 adrenergic receptor subtypes, and that these subtypes are differentially located in the relevant ocular tissues. 
Several techniques have been used to define the localization ofα 2 adrenergic receptors in the human eye. Autoradiographic studies found high levels of α2 adrenergic receptors in the iris epithelium and ciliary epithelium, as well as in the ciliary muscle, retina, and RPE. 30 In these studies, the total pool of α2 receptors was visualized, but the individual receptor subtypes were not considered. In the human ciliary body, immunofluorescence labeling indicates the presence of theα 2B and α2C subtypes, but not theα 2A subtype. 20 In contrast to these immunofluorescence results, our radioligand-binding data indicate that the α2A is the main, if not the only, subtype present in the human ciliary body, iris, and RPE–choriocapillaris. The neurosensory retina appears to contain mostly α2A and perhaps some α2C. This conclusion is based on a comparison of K i values in the ocular tissues with previous data from our laboratory with the cloned human subtypes expressed in COS cells. 26 Our conclusion that theα 2A is the major subtype in human ocular tissues is consistent with radioligand-binding studies in the cow, rabbit, and pig, which also identify the α2A subtype as the main ocular subtype. 16 18 19  
In contrast to our results from the radioligand-binding technique are the results obtained using PCR and immunofluorescence techniques. Two studies have used PCR to determine the absence or presence of mRNA encoding the three α2 adrenergic receptor subtypes in the human eye. In a transformed cell line of human nonpigmented epithelium, PCR studies indicate the presence of mRNA for the α2B andα 2C subtypes, but not theα 2A. 21 In a second, similar study published thus far only in abstract form, the PCR technique indicated the presence of only the α2B subtype in a transformed cell line of human nonpigmented epithelium and in the human ciliary body. 21 Both studies also examined rabbit iris–ciliary body. The former study found evidence for mRNA for all three subtypes, whereas the latter study found only the α2A andα 2B subtypes. The single study using the immunofluorescence technique suggested the presence of theα 2B and α2C subtypes, but not theα 2A, in the human ciliary body. 20 By contrast all three subtypes were found in the rabbit iris–ciliary body. Thus, although these two techniques appear to differ on exactly which subtypes are present in human and rabbit ocular tissues, they agree that the α2A subtype is absent in human tissues studied. This conclusion is not supported by the results of the radioligand-binding studies reported here. 
It is of interest that the immunofluorescence technique identifies all three subtypes in the rabbit ciliary body, 20 whereas the radioligand-binding approach finds only the α2A subtype. 19 Because immunofluorescence is not a quantitative approach, it may be that the other two subtypes are present in such low concentrations in the rabbit ciliary body that they are not detected by the radioligand-binding technique, or that they are not functional (i.e., unable to bind ligand) proteins. That there was no immunofluorescence detection of the α2A subtype in the human ciliary body is of concern, because this is the major subtype detected by the radioligand technique in all four species investigated to date: human, cow, pig, and rabbit. Furthermore, the cultured human trabecular meshwork cells express only the α2A subtype. 31 As Huang et al. 20 point out, theα 2A subtype may well exist in the human eye but was not detected in their immunofluorescence experiments, perhaps because the antibody used was not sufficiently sensitive. However, the PCR studies should have detected the mRNA for the α2A subtype if it were present. Similarly, it is possible that the α2B andα 2C subtypes are present at low density in the human ciliary body, and thus were not detected by the radioligand technique because of the presence of a much higher density of theα 2A subtype. Another potential resolution to the difference in conclusions reached by the two techniques is one of receptor subtype localization, because the radioligand-binding technique detects the binding in the tissue as a whole, whereas the immunofluorescence experiments detect receptors only in a small area. Thus, the α2A subtype could be the major subtype in the ciliary body but did not happen to be in the specific place studied in the immunofluorescence experiments. Conversely, the α2B and α2C subtypes may be localized to the specific places studied in the immunofluorescence experiments, but not sufficiently widely distributed to be detected by the radioligand-binding technique. 
Based on the data in Figure 5 , it appears probable that someα 2C (or possibly α2B) receptors are present in the neurosensory retina. A firm conclusion cannot be drawn, however, because the data were significantly better fit by a two-site model in only four of the six individual experiments. In addition, the IC50 values for spiroxatrine derived from Figure 5 (3.7μ M and 104 μM) do not agree well with the K i values determined for the human clones (5.5, 0.19, 0.13 μM) for the α2A, α2B, and α2C subtypes, respectively. 26 The low density of α2 adrenergic receptors in the neurosensory retina and the limited availability of human tissue make it difficult to resolve this issue clearly. 
The density of α2 adrenergic receptors has now been determined in one or more ocular tissues in four species, as is summarized in Fig. 6 . It is remarkable that the relative density in the four tissues is different in each species and that the highest density for each tissue is found in a different species. For example, in the cow, the receptor density in the neurosensory retina is approximately 100 times higher than in the human. The significance of this marked species variability is unknown at the present time. Furthermore, it must be emphasized that receptor density does not necessarily relate to either its physiological or pharmacologic importance. 
The pineal gland and the neurosensory retina share many similarities including light sensitivity and embryonic origins. In the pineal gland, the β adrenergic receptor shows similar species variations in density. The sheep pineal has a very high density of β adrenergic receptors (4400 femtomoles/mg protein 32 ), the rat is approximately 10 times lower (550 femtomoles/mg protein 33 ), and the human (35 femtomoles/mg protein 34 ) and hamster (55 femtomoles/mg protein 33 ) are 10 times lower yet. By contrast, theα 2 receptor density is relatively constant in the three species that have been examined to date: human, 63 femtomoles/mg protein (David Bylund, unpublished); cow, 71 femtomoles/mg protein 35 ; and rat, 69 femtomoles/mg protein. 36  
Some α2 adrenergic agents, including those used in the treatment of glaucoma, also bind to the nonadrenergic imidazoline sites. The I1 imidazoline site may have a role in regulating blood pressure, 37 but its role, if any, in regulating intraocular pressure is unknown. 38 39 Our studies do not address this issue because the radioligand that we chose ([3HRX821002) has a low affinity for imidazoline sites 40 and thus would not bind to those sites under the conditions of our assay. In addition, norepinephrine, which does not bind to imidazoline sites, was used to define nonspecific binding in our studies, thereby eliminating any contribution of imidazoline sites to our data. 
Alpha-2 adrenergic agonists are increasingly used in glaucoma therapy. There is some evidence to suggest that these agents may have some direct neuroprotective effect on the optic nerve in addition to the protective effect of reduced intraocular pressure. 41 42 However, long-term studies are needed to evaluate the extent to whichα 2 adrenergic agents preserve visual function. Attempts to design new α2 agents with increased specificity and thus fewer side effects will be strengthened by a better understanding of the α2 adrenergic receptor subtype(s) mediating the ocular hypotensive effects of these agents. 
 
Figure 1.
 
Saturation radioligand-binding experiments of α2 adrenergic receptors. Membrane preparations from four human ocular tissues were incubated with various concentrations of[ 3H]RX821002 (Free) and the specific binding (Bound) determined. Specific binding was calculated as the difference between the total binding and the nonspecific binding (100 μM norepinephrine). The results presented are from a single experiment, and the mean ± SEM of four similar experiments are presented in Table 1 . (A) The results as a hyperbolic saturation curve, determined by nonlinear regression. (B) Data have been transformed to a Rosenthal plot that linearizes the data. 25
Figure 1.
 
Saturation radioligand-binding experiments of α2 adrenergic receptors. Membrane preparations from four human ocular tissues were incubated with various concentrations of[ 3H]RX821002 (Free) and the specific binding (Bound) determined. Specific binding was calculated as the difference between the total binding and the nonspecific binding (100 μM norepinephrine). The results presented are from a single experiment, and the mean ± SEM of four similar experiments are presented in Table 1 . (A) The results as a hyperbolic saturation curve, determined by nonlinear regression. (B) Data have been transformed to a Rosenthal plot that linearizes the data. 25
Table 1.
 
Affinity (K d) and Density (B max) of α2 Adrenergic Receptor Sites Determined by [3H]RX821002 Binding
Table 1.
 
Affinity (K d) and Density (B max) of α2 Adrenergic Receptor Sites Determined by [3H]RX821002 Binding
Tissue K d B max
Ciliary Body 0.225 ± 0.011 87 ± 7
RPE–choriocapillaris 0.225 ± 0.009 95 ± 6
Iris 0.220 ± 0.012 440 ± 50
Neurosensory retina 0.320 ± 0.003 14 ± 2
Figure 2.
 
Inhibition radioligand-binding experiments of ciliary bodyα 2 adrenergic receptors. Membrane preparations of human ciliary body were incubated with various concentrations of the indicated adrenergic agents and with 0.24 nM[ 3H]RX821002. The data are presented as the percentage of specific binding in the absence of any inhibitor. Specific binding was calculated as the difference between total binding and nonspecific binding. Typical levels of total binding and nonspecific binding in cpm were: 1000 and 200 (iris); 550 and 120 (ciliary body); 750 and 150 (RPE–choriocapillaris); 120 and 35 (neurosensory retina). The IC50 values, determined by nonlinear regression, were used to calculate K i values. The results presented are from a single experiment, and the mean ± SEM of three similar experiments are presented in Table 2 .
Figure 2.
 
Inhibition radioligand-binding experiments of ciliary bodyα 2 adrenergic receptors. Membrane preparations of human ciliary body were incubated with various concentrations of the indicated adrenergic agents and with 0.24 nM[ 3H]RX821002. The data are presented as the percentage of specific binding in the absence of any inhibitor. Specific binding was calculated as the difference between total binding and nonspecific binding. Typical levels of total binding and nonspecific binding in cpm were: 1000 and 200 (iris); 550 and 120 (ciliary body); 750 and 150 (RPE–choriocapillaris); 120 and 35 (neurosensory retina). The IC50 values, determined by nonlinear regression, were used to calculate K i values. The results presented are from a single experiment, and the mean ± SEM of three similar experiments are presented in Table 2 .
Table 2.
 
Affinities (K i) of Adrenergic Drugs of Ocularα 2 Adrenergic Receptors as Determined by[ 3H]RX821002 Binding
Table 2.
 
Affinities (K i) of Adrenergic Drugs of Ocularα 2 Adrenergic Receptors as Determined by[ 3H]RX821002 Binding
Drug Ciliary Body RPE-Choriocapillaris Iris Neurosensory Retina
K i SEM Slope n K i SEM Slope n K i SEM Slope n K i SEM Slope n
Rauwolscine 0.99 0.06 1.02 3 1.12 0.06 1.03 3 1.07 0.11 1.01 3 0.43 0.07 0.80 2
Oxymetazoline 4.5 0.4 1.15 3 3.1 0.2 0.95 4 3.1 0.2 0.96 2 6.7 0.8 0.82 3
WB4101 6.6 0.1 0.99 3 7.1 0.2 0.99 3 13 2 1.29 3 3.0 0.0 0.80 2
Spiroxatrine 26 2 1.13 3 25 1 1.10 6 42 2 1.08 2 4.2 0.4 0.81 6
ARC-239 499 21 1.09 3 492 23 1.01 3 530 42 1.08 3 284 23 1.00 3
Prazosin 1419 66 1.37 3 2319 180 1.56 3 851 157 1.21 3 177 14 0.73 2
Norepinephrine 2944 128 0.71 3 4147 278 0.87 3 3360 143 0.91 3 2468 161 0.78 2
Table 3.
 
Relative Affinities of Adrenergic Antagonists for Humanα 2 Adrenergic Receptor Subtypes
Table 3.
 
Relative Affinities of Adrenergic Antagonists for Humanα 2 Adrenergic Receptor Subtypes
Antagonist α2A α2B α2C
Rauwolscine 1.0 1.2 0.41
Oxymetazoline 1.0 230 9.4
WB4101 1.0 4.7 0.44
Spiroxatrine 1.0 0.03 0.02
ARC-239 1.0 0.02 0.03
Prazosin 1.0 0.10 0.04
Figure 3.
 
The correlation of pK i values of adrenergic antagonists for human ciliary body with the human RPE–choriocapillaris (A), iris (B), and neurosensory retina (C). The data are taken from Tables 1 and 2 . The correlation coefficients (r) are also shown. A summary of the correlation coefficients is presented in Table 4 .
Figure 3.
 
The correlation of pK i values of adrenergic antagonists for human ciliary body with the human RPE–choriocapillaris (A), iris (B), and neurosensory retina (C). The data are taken from Tables 1 and 2 . The correlation coefficients (r) are also shown. A summary of the correlation coefficients is presented in Table 4 .
Figure 4.
 
The correlation of pK i values (logarithm of the K i or K d values) of adrenergic antagonists for ciliary body with the cloned human α2 adrenergic receptor subtypes α2A (A), α2B (B), and α2C (C). The data are taken from Tables 1 and 2 and from Berlie et al. 16 The correlation coefficients (r), are also shown. A summary of the correlation coefficients for all four human ocular tissues with the three cloned human α2 adrenergic receptor subtypes is shown in Table 4 .
Figure 4.
 
The correlation of pK i values (logarithm of the K i or K d values) of adrenergic antagonists for ciliary body with the cloned human α2 adrenergic receptor subtypes α2A (A), α2B (B), and α2C (C). The data are taken from Tables 1 and 2 and from Berlie et al. 16 The correlation coefficients (r), are also shown. A summary of the correlation coefficients for all four human ocular tissues with the three cloned human α2 adrenergic receptor subtypes is shown in Table 4 .
Table 4.
 
Correlation Coefficients (r) from Correlations of pK i Values Between Human Ocular Tissues and the Cloned Human α2 Adrenergic Receptor Subtypes
Table 4.
 
Correlation Coefficients (r) from Correlations of pK i Values Between Human Ocular Tissues and the Cloned Human α2 Adrenergic Receptor Subtypes
Ciliary Body Cloned Subtypes
α2A α2B α2C
Ciliary Body 0.974 0.22 0.50
RPE–choriocapillaris 0.998 0.967 0.19 0.46
Iris 0.995 0.945 0.15 0.41
Neurosensory retina 0.965 0.974 0.39 0.66
Figure 5.
 
Inhibition of [3H]RX821002 binding to theα 2 adrenergic receptors in the neurosensory retina by spiroxatrine. The data shown are the merged data from six experiments. Each data point is the mean of duplicate determinations. A two-site model fit the data significantly better than a one-site model (F = 5.0; P = 0.009). The higher affinity site had an EC50 of 3.7 nM and accounted for 74% of the receptors, whereas the lower affinity site had an EC50 of 104 nM.
Figure 5.
 
Inhibition of [3H]RX821002 binding to theα 2 adrenergic receptors in the neurosensory retina by spiroxatrine. The data shown are the merged data from six experiments. Each data point is the mean of duplicate determinations. A two-site model fit the data significantly better than a one-site model (F = 5.0; P = 0.009). The higher affinity site had an EC50 of 3.7 nM and accounted for 74% of the receptors, whereas the lower affinity site had an EC50 of 104 nM.
Figure 6.
 
The density (B max) of ocularα 2 adrenergic receptors in various species. The data for the human are from Table 1 , the data for the cow, pig, and rabbit (ciliary body was the only tissue studied in rabbit) are from Bylund et al., 17 Wikberg–Matsson et al., 18 and Jin et al., 19 respectively.
Figure 6.
 
The density (B max) of ocularα 2 adrenergic receptors in various species. The data for the human are from Table 1 , the data for the cow, pig, and rabbit (ciliary body was the only tissue studied in rabbit) are from Bylund et al., 17 Wikberg–Matsson et al., 18 and Jin et al., 19 respectively.
The authors thank Ronald J. Walkenbach and the Missouri Lions Eye Tissue Bank, Columbia, for the human eyes used in this study and Laurie J. Iversen for excellent technical assistance. 
Alward WLM. Medical management of glaucoma. N Engl J Med. 1998;339:1298–1307. [CrossRef] [PubMed]
Chacko DM, Camras CB. The potential of α2-adrenergic agonists in the medical treatment of glaucoma. Curr Opin Ophthalmol. 1994;5:76–84.
Walters TR. Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies. Survey Ophthalmol. 1996;41:S19–S26. [CrossRef]
Wilensky JT. The role of brimonidine in the treatment of open-angle glaucoma. Survey Ophthalmol. 1996;41:S3–S7. [CrossRef]
Serle JB. Pharmacological advances in the treatment of glaucoma. Drugs Aging. 1994;5:156–170. [CrossRef] [PubMed]
Toris CB, Tafoya ME, Camras CB, et al. Effects of apraclonidine on aqueous humor dynamics in human eyes. Ophthalmology. 1995;102:456–461. [CrossRef] [PubMed]
Toris CB, Gleason M, Camras CB, et al. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol. 1995;113:1514–1517. [CrossRef] [PubMed]
Bylund DB. Subtypes of α2-adrenoceptors: pharmacological and molecular biological evidence converge. Trends Pharmacol Sci. 1988;9:356–361. [CrossRef] [PubMed]
Bylund DB. Subtypes of α1- and α2-adrenergic receptors. FASEB J.. 1992;6:832–839. [PubMed]
Bylund DB, Ray-Prenger C, Murphy TJ. Alpha-2A and alpha-2B adrenergic receptor subtypes: antagonist binding in tissues and cell lines containing only one subtype. J Pharmacol Exp Ther. 1988;245:600–607. [PubMed]
Murphy TJ, Bylund DB. Characterization of alpha-2 adrenergic receptors in the OK cell, an opossum kidney cell line. J Pharmacol Exp Ther. 1988;244:571–578. [PubMed]
Blaxall HS, Murphy TJ, Baker JC, et al. Characterization of the alpha-2C adrenergic receptor subtype in the opossum kidney and in the OK cell line. J Pharmacol Exp Ther. 1991;259:323–329. [PubMed]
Kobilka BK, Matsui H, Kobilka TS, et al. Cloning, sequencing, and expression of the gene encoding for the human platelet α2-adrenergic receptor subtypes. Science. 1987;238:650–656. [CrossRef] [PubMed]
Regan JW, Kobilka TS, Yang-Feng TL, et al. Cloning and expression of a human kidney cDNA for an α2-adrenergic receptor subtype. Proc Natl Acad Sci USA. 1988;85:6301–6305. [CrossRef] [PubMed]
Weinshank RL, Zgombick JM, Macchi M, et al. Cloning, expression, and pharmacological characterization of a human α 2B-adrenergic receptor. Mol Pharmacol. 1990;35:681–688.
Berlie JR, Iversen LJ, Blaxall HS, et al. Alpha-2 adrenergic receptors in the bovine retina: presence of only the alpha-2D subtype. Invest Ophthalmol Vis Sci. 1995;36:1885–1892. [PubMed]
Bylund DB, Iversen LJ, Matulka WJ, et al. Characterization of alpha-2 adrenergic receptor subtypes in bovine ocular tissue homogenates. J Pharmacol Exp Ther. 1997;281:1171–1177. [PubMed]
Wikberg-Matsson A, Wikberg JES, Uhlén S. Characterization of α2-adrenoceptor subtypes in the porcine eye: identification of α2A-adrenoceptors in the choroid, ciliary body and iris, and α2A- and α2C-adrenoceptors in the retina. Exp Eye Res. 1996;63:57–65. [CrossRef] [PubMed]
Jin Y, Verstappen A, Yorio T. Characterization of α2-adrenoceptor binding sites in rabbit ciliary body membranes. Invest Ophthalmol Vis Sci. 1994;35:2500–2508. [PubMed]
Huang Y, Gil DW, Vanscheeuwijck P, et al. Localization of α2-adrenergic receptor subtypes in the anterior segment of the human eye with selective antibodies. Invest Ophthalmol Vis Sci. 1995;36:2729–2739. [PubMed]
Yorio T, Jin Y. Identification of alpha-2 adrenoceptor subtype mRNA in the ciliary body [ARVO Abstract]. Invest Ophthalmol Vis Sci. 1995;36(4):S139. Abstract nr 677.
Deupree JD, Hinton KA, Cerutis DR, et al. Buffers differentially alter the binding of [3H]rauwolscine and [3H]RX821002 to the alpha-2 adrenergic receptor subtypes. J Pharmacol Exp Ther. 1996;278:1215–1227. [PubMed]
Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–254. [CrossRef] [PubMed]
Cheng Y-C, Prusoff WH. Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973;22:3099–3108. [CrossRef] [PubMed]
Rosenthal HE. Graphical method for the determination and presentation of binding parameters in a complex system. Anal Biochem. 1967;20:525–532. [CrossRef] [PubMed]
Bylund DB, Blaxall HS, Iversen LJ, et al. Pharmacological characteristics of α2-adrenergic receptors: comparison of pharmacologically defined subtypes with subtypes identified by molecular cloning. Mol Pharmacol. 1992;42:1–5. [PubMed]
Gleason MM, Hieble JP. The α2-adrenoceptors of the human retinoblastoma cell line (Y79) may represent an additional example of the α2C-adrenoceptor. Br J Pharmacol. 1992;107:222–225. [CrossRef] [PubMed]
Schadlu R, Maus TL, Nau CB, et al. Comparison of the efficacy of apraclonidine and brimonidine as aqueous suppressants in humans. Arch Ophthalmol. 1998;116:1441–1444. [CrossRef] [PubMed]
Wang R-F, Lee P-Y, Taniguchi T, et al. Effect of oxymetazoline on aqueous humor dynamics and ocular blood flow in monkeys and rabbits. Arch Ophthalmol. 1993;111:535–538. [CrossRef] [PubMed]
Matsuo T, Cynader MS. Localization of alpha-2 adrenergic receptors in the human eye. Ophthalmic Res. 1992;24:213–219. [CrossRef] [PubMed]
Stamer WD, Huang Y, Seftor REB, et al. Cultured human trabecular meshwork cells express functional α2A adrenergic receptors. Invest Ophthalmol Vis Sci. 1996;37:2426–2433. [PubMed]
Foldes A, Maxwell CA, Hinks NT, et al. Effects of steroids on beta-adrenergic binding sites in sheep pineal glands. Biochem Pharmacol. 1982;31:1369–1374. [CrossRef] [PubMed]
Craft CM, Morgan WW, Jones DJ, et al. Hamster and rat pineal gland beta-adrenoceptor characterization with iodocyanopindolol and the effect of decreased catecholamine synthesis on the receptor. J Pineal Res. 1985;2:51–66. [CrossRef] [PubMed]
Little KY, Kirkman JA, Duncan GE. β-Adrenergic receptor subtypes in human pineal gland. J Pineal Res. 1996;20:15–20. [CrossRef] [PubMed]
Simonneaux V, Ebadi M, Bylund DB. Identification and characterization of α2d-adrenergic receptors in bovine pineal gland. Mol Pharmacol. 1991;40:235–241. [PubMed]
Schaad NC, Klein DC. Characterization of alpha 2-adrenergic receptors on rat pinealocytes. Endocrinology. 1992;130:2804–2810. [PubMed]
Eglen RM, Hudson AL, Kendall DA, et al. “Seeing through a glass darkly”: casting light on imidazoline “I” sites. Trends Pharmacol Sci. 1998;19:381–390. [CrossRef] [PubMed]
Chu TC, Wong W, Gluchowski C, et al. Rilmenidine-induced ocular hypotension: role of imidazoline1 and alpha2 receptors. Curr Eye Res. 1996;15:943–950. [CrossRef] [PubMed]
Munk SA, Lai RK, Burke JE, et al. Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent. J Med Chem. 1996;39:1193–1195. [CrossRef] [PubMed]
Miralles A, Olmos G, Sastre M, et al. Discrimination and pharmacological characterization of I2-imidazoline sites with [3H]idazoxan and alpha-2 adrenoceptors with [3H]RX821002 (2-methoxy idazoxan) in the human and rat brains. J Pharmacol Exp Ther. 1993;264:1187–1197. [PubMed]
Wen R, Cheng T, Li YW, et al. α2-adrenergic agonists induce basic fibroblast growth factor expression in photoreceptors in vivo and ameliorate light damage. J Neurosci. 1996;16:5986–5992. [PubMed]
Yoles E, Wheeler LA, Schwartz M. α 2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration. Invest Ophthalmol Vis Sci. 1999;40:65–73. [PubMed]
Figure 1.
 
Saturation radioligand-binding experiments of α2 adrenergic receptors. Membrane preparations from four human ocular tissues were incubated with various concentrations of[ 3H]RX821002 (Free) and the specific binding (Bound) determined. Specific binding was calculated as the difference between the total binding and the nonspecific binding (100 μM norepinephrine). The results presented are from a single experiment, and the mean ± SEM of four similar experiments are presented in Table 1 . (A) The results as a hyperbolic saturation curve, determined by nonlinear regression. (B) Data have been transformed to a Rosenthal plot that linearizes the data. 25
Figure 1.
 
Saturation radioligand-binding experiments of α2 adrenergic receptors. Membrane preparations from four human ocular tissues were incubated with various concentrations of[ 3H]RX821002 (Free) and the specific binding (Bound) determined. Specific binding was calculated as the difference between the total binding and the nonspecific binding (100 μM norepinephrine). The results presented are from a single experiment, and the mean ± SEM of four similar experiments are presented in Table 1 . (A) The results as a hyperbolic saturation curve, determined by nonlinear regression. (B) Data have been transformed to a Rosenthal plot that linearizes the data. 25
Figure 2.
 
Inhibition radioligand-binding experiments of ciliary bodyα 2 adrenergic receptors. Membrane preparations of human ciliary body were incubated with various concentrations of the indicated adrenergic agents and with 0.24 nM[ 3H]RX821002. The data are presented as the percentage of specific binding in the absence of any inhibitor. Specific binding was calculated as the difference between total binding and nonspecific binding. Typical levels of total binding and nonspecific binding in cpm were: 1000 and 200 (iris); 550 and 120 (ciliary body); 750 and 150 (RPE–choriocapillaris); 120 and 35 (neurosensory retina). The IC50 values, determined by nonlinear regression, were used to calculate K i values. The results presented are from a single experiment, and the mean ± SEM of three similar experiments are presented in Table 2 .
Figure 2.
 
Inhibition radioligand-binding experiments of ciliary bodyα 2 adrenergic receptors. Membrane preparations of human ciliary body were incubated with various concentrations of the indicated adrenergic agents and with 0.24 nM[ 3H]RX821002. The data are presented as the percentage of specific binding in the absence of any inhibitor. Specific binding was calculated as the difference between total binding and nonspecific binding. Typical levels of total binding and nonspecific binding in cpm were: 1000 and 200 (iris); 550 and 120 (ciliary body); 750 and 150 (RPE–choriocapillaris); 120 and 35 (neurosensory retina). The IC50 values, determined by nonlinear regression, were used to calculate K i values. The results presented are from a single experiment, and the mean ± SEM of three similar experiments are presented in Table 2 .
Figure 3.
 
The correlation of pK i values of adrenergic antagonists for human ciliary body with the human RPE–choriocapillaris (A), iris (B), and neurosensory retina (C). The data are taken from Tables 1 and 2 . The correlation coefficients (r) are also shown. A summary of the correlation coefficients is presented in Table 4 .
Figure 3.
 
The correlation of pK i values of adrenergic antagonists for human ciliary body with the human RPE–choriocapillaris (A), iris (B), and neurosensory retina (C). The data are taken from Tables 1 and 2 . The correlation coefficients (r) are also shown. A summary of the correlation coefficients is presented in Table 4 .
Figure 4.
 
The correlation of pK i values (logarithm of the K i or K d values) of adrenergic antagonists for ciliary body with the cloned human α2 adrenergic receptor subtypes α2A (A), α2B (B), and α2C (C). The data are taken from Tables 1 and 2 and from Berlie et al. 16 The correlation coefficients (r), are also shown. A summary of the correlation coefficients for all four human ocular tissues with the three cloned human α2 adrenergic receptor subtypes is shown in Table 4 .
Figure 4.
 
The correlation of pK i values (logarithm of the K i or K d values) of adrenergic antagonists for ciliary body with the cloned human α2 adrenergic receptor subtypes α2A (A), α2B (B), and α2C (C). The data are taken from Tables 1 and 2 and from Berlie et al. 16 The correlation coefficients (r), are also shown. A summary of the correlation coefficients for all four human ocular tissues with the three cloned human α2 adrenergic receptor subtypes is shown in Table 4 .
Figure 5.
 
Inhibition of [3H]RX821002 binding to theα 2 adrenergic receptors in the neurosensory retina by spiroxatrine. The data shown are the merged data from six experiments. Each data point is the mean of duplicate determinations. A two-site model fit the data significantly better than a one-site model (F = 5.0; P = 0.009). The higher affinity site had an EC50 of 3.7 nM and accounted for 74% of the receptors, whereas the lower affinity site had an EC50 of 104 nM.
Figure 5.
 
Inhibition of [3H]RX821002 binding to theα 2 adrenergic receptors in the neurosensory retina by spiroxatrine. The data shown are the merged data from six experiments. Each data point is the mean of duplicate determinations. A two-site model fit the data significantly better than a one-site model (F = 5.0; P = 0.009). The higher affinity site had an EC50 of 3.7 nM and accounted for 74% of the receptors, whereas the lower affinity site had an EC50 of 104 nM.
Figure 6.
 
The density (B max) of ocularα 2 adrenergic receptors in various species. The data for the human are from Table 1 , the data for the cow, pig, and rabbit (ciliary body was the only tissue studied in rabbit) are from Bylund et al., 17 Wikberg–Matsson et al., 18 and Jin et al., 19 respectively.
Figure 6.
 
The density (B max) of ocularα 2 adrenergic receptors in various species. The data for the human are from Table 1 , the data for the cow, pig, and rabbit (ciliary body was the only tissue studied in rabbit) are from Bylund et al., 17 Wikberg–Matsson et al., 18 and Jin et al., 19 respectively.
Table 1.
 
Affinity (K d) and Density (B max) of α2 Adrenergic Receptor Sites Determined by [3H]RX821002 Binding
Table 1.
 
Affinity (K d) and Density (B max) of α2 Adrenergic Receptor Sites Determined by [3H]RX821002 Binding
Tissue K d B max
Ciliary Body 0.225 ± 0.011 87 ± 7
RPE–choriocapillaris 0.225 ± 0.009 95 ± 6
Iris 0.220 ± 0.012 440 ± 50
Neurosensory retina 0.320 ± 0.003 14 ± 2
Table 2.
 
Affinities (K i) of Adrenergic Drugs of Ocularα 2 Adrenergic Receptors as Determined by[ 3H]RX821002 Binding
Table 2.
 
Affinities (K i) of Adrenergic Drugs of Ocularα 2 Adrenergic Receptors as Determined by[ 3H]RX821002 Binding
Drug Ciliary Body RPE-Choriocapillaris Iris Neurosensory Retina
K i SEM Slope n K i SEM Slope n K i SEM Slope n K i SEM Slope n
Rauwolscine 0.99 0.06 1.02 3 1.12 0.06 1.03 3 1.07 0.11 1.01 3 0.43 0.07 0.80 2
Oxymetazoline 4.5 0.4 1.15 3 3.1 0.2 0.95 4 3.1 0.2 0.96 2 6.7 0.8 0.82 3
WB4101 6.6 0.1 0.99 3 7.1 0.2 0.99 3 13 2 1.29 3 3.0 0.0 0.80 2
Spiroxatrine 26 2 1.13 3 25 1 1.10 6 42 2 1.08 2 4.2 0.4 0.81 6
ARC-239 499 21 1.09 3 492 23 1.01 3 530 42 1.08 3 284 23 1.00 3
Prazosin 1419 66 1.37 3 2319 180 1.56 3 851 157 1.21 3 177 14 0.73 2
Norepinephrine 2944 128 0.71 3 4147 278 0.87 3 3360 143 0.91 3 2468 161 0.78 2
Table 3.
 
Relative Affinities of Adrenergic Antagonists for Humanα 2 Adrenergic Receptor Subtypes
Table 3.
 
Relative Affinities of Adrenergic Antagonists for Humanα 2 Adrenergic Receptor Subtypes
Antagonist α2A α2B α2C
Rauwolscine 1.0 1.2 0.41
Oxymetazoline 1.0 230 9.4
WB4101 1.0 4.7 0.44
Spiroxatrine 1.0 0.03 0.02
ARC-239 1.0 0.02 0.03
Prazosin 1.0 0.10 0.04
Table 4.
 
Correlation Coefficients (r) from Correlations of pK i Values Between Human Ocular Tissues and the Cloned Human α2 Adrenergic Receptor Subtypes
Table 4.
 
Correlation Coefficients (r) from Correlations of pK i Values Between Human Ocular Tissues and the Cloned Human α2 Adrenergic Receptor Subtypes
Ciliary Body Cloned Subtypes
α2A α2B α2C
Ciliary Body 0.974 0.22 0.50
RPE–choriocapillaris 0.998 0.967 0.19 0.46
Iris 0.995 0.945 0.15 0.41
Neurosensory retina 0.965 0.974 0.39 0.66
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×